to be involved in the pro-inflammatory and proatherogenic processes in an in vitro culturing assay system. 14 In addition, the same group subsequently found that galectin-2 (LGALS2) was a key ligand for LTA, while the most important SNP was also identified. 14 The 3279C/T SNP in intron-1 was associated with a markedly reduced level of the LGALS2 transcript. In more than 4,000 MI cases and controls, a significantly reduced risk for MI shows that T homozygosity seems to have a protective effect on AMI. 10 These findings show that a potential key inflammation pathway, the LTA cascade, which is strengthened by the identification of genes for both a ligand and its receptor, both strongly associated with MI. Likewise, both galectin-2 and LTA were detected for expression in smooth muscle cells and macrophages in human atherosclerotic lesions. 15 These 2 genes were highly suspected with its interaction in vivo in modulating proatherogenic processes, finally resulting in an AMI onset. 15 Ethnic differences of genetic variants contribute to disease risks, according to experiences from these kinds of studies. We are also interested in the polymorphisms of 2 gene influences on the onset or prognosis of AMI among the Taiwanese population, and then comparing such findings with studies on the Japanese population since both belong to the eastern Asian ethnic origin. The Taiwanese may have similar genetic compositions with the Japanese cohorts. The conduct of the case-control study was to discriminate the genetic impact of the polymorphisms of these 2 genes at the onset of AMI.
Materials and Methods

Patients
We studied 117 Taiwanese patients with AMI who were registered for a Cardiovascular Disease Study from January 2006 to September 2006 at the Cardiology Division of Kaoshiung
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Inflammation gene polymorphisms contributing to pro-atherosclerosis and pro-inflammation processes of infracted hearts were intensively investigated. In this study, we performed a case-control study involving 117 acute myocardial infarction (AMI) patients versus 165 unrelated normal subjects to distinguish associations of the onset of AMI with 252A/G, 804C/A polymorphisms of Lymphotoxin-alpha (LTA, also named TNF-β) gene, and 3279 C/T polymorphism of its binding partner, LGALS2 gene. An association concordant to the original study between LTA 252G and 804A homozygosity with the onset of AMI was found. In addition, 804C/A polymorphism more generally correlated to the prevalence of coronary artery disease (CAD) rather than the onset of AMI. The susceptible haplotype of LTA to AMI risk was found as the 252G allele couple with 804C or 804A allele among the Taiwanese population. More populationbased studies are warranted to confirm these findings and evaluate its clinical impact on AMI diagnosis and prognosis. . All AMI patients underwent coronary angiography and left ventriculography. The diagnosis of AMI was based on typical electrocardiographic changes and increased serum activities of enzymes. Diagnosis was confirmed by the detection of a wall motion abnormality by left ventriculography and associated stenosis in any major coronary artery or in the left main trunk by coronary angiography. All control subjects were tested by normal electrocardiograms at rest and showed no signs of myocardial ischemia on exercise stress testing. All participants of this study provided written informed consent for data collection, blood sampling, and genetic genotyping. All patients were prospectively registered immediately after diagnosis of AMI based on their symptoms, electrocardiographic findings, and release of cardiac enzymes. In some cases, they completed the informed consent upon return for outpatient services and further exams. The study protocol was approved by the International Review Board and complied with the Guidelines for Genetic Research of Kaohsiung Armed Forces General Hospital.
Genotyping
Peripheral blood (4 mL) was collected from each subject into vacuum tubes containing 50 mmol/L ethylenediaminetetraacetic acid (EDTA). Genomic DNA was isolated with NucleoSpin Blood Genomic DNA kit (Macherey-Nagel, Duren, Germany). Genotypes for 252A/G, 804C/A polymorphisms of LTA gene, and 3279C/T polymorphism of the LGALS2 gene were determined with an allele-specific polymerase chain reaction (PCR) assay. Polymorphic regions of the gene were amplified by PCR with 2 allele-specific sense primers (5'-CACATTCTCTGTTTCTGCCATXGT-3' for 252A/G; 5'-GTGAGCAGCAGGTTTGAGXGT-3' for 804C/A) or (5'-CACATTCTCTGTTT CTGCCATXAT-3' for 252A/G; 5'-GTGAGCAGCAGGTTTGAGXTT-3' for 804C/A), and with an antisense primer (5'-GTCAGAGAAACCCCA-AGGTGAG-3' for 252A/G; 5'-ACACCTTCAGCTGC-CCAGAC-3' for 804C/A). The reaction mixture was 20 μL containing 100 ng DNA, 10 pmol of each primer, 0.25 mmol/L of premixed deoxynucleoside triphosphate, 0.5 mmol/L, and 1 U YEA Taq polymerase (Yeastern Biotech, Taipei, Taiwan). Polymerase chain reaction conditions for the LTA amplification comprised an initial denaturation at 94°C for 5 minutes; 35 cycles of denaturation at 94°C for 15 seconds, annealing at 54°C (252A/G wild-type specific PCR) or 56°C (252A/G mutant-specific PCR and 804C/A wild-type, mutant-specific PCR) for 30 seconds, and extension at 72°C for 30 seconds; and a final extension at 72°C for 7 minutes. For amplification of LGALS2, allele-specific primers (upstream primers: 5'-ACACTCACAGACGTG TGCCCTGCGCA-CACACAXAT-3' was used for T allele; 5'-ACACTCACA-GACG TGTGCCCTGCGCACACACAXGT-3' for C allele; and downstream primer: 5'-GTGTGGGTGCTTCTCT-TAGTC-3'). The 2-step PCR condition was as follows: initial denaturation at 94°C for 5 minutes; 10 cycles of denaturation at 95°C for 15 seconds, annealing at 52°C for 30 seconds, and extension at 72°C for 30 seconds; and 20 cycles of denaturation at 94°C for 15 seconds, annealing at 55°C for 45 seconds, and extension at 72°C for 45 seconds. The amplified DNA was separated by 2% Amresco Agarose I agarose (Amresco, Solon, OH), then stained with 0.5ug/mL ethidium bromide solution, and visualized by Stratagene Eagle Eyes II UV transilluminator (Stratagene, La Jolla, CA) ( Figure 1) . The gel image was recorded by a digital gel documentation system. To confirm the accuracy of genotyping by this method, we randomly selected 10% DNA samples and subjected them to direct DNA sequencing (Figure 2) . In each instance, the genotype determined by the allele-specific PCR assay system was identical to those determined by confirmatory methods. In addition, the genotype of each polymorphism was confirmed by at least 2 well-trained laboratory technicians. LGALS2 23279 C/T polymorphism was amplified by using allele-specific PCR as described in Materials and Methods. Two independent PCR reactions for allele-specific amplification of each clinical sample were performed. The PCR products were loaded into adjacent lanes, and the gel image revealed 3 typical genotypes of this polymorphism. M1: 100 bp marker; M2: 25 bp marker. The PCR products are indicated with an arrow.
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Statistical Analysis
Experimental data of gene polymorphisms were converted into categorical variables and compared by a χ 2 test and a spearman correlation test to distinguish the significance of variation between each subject. Allele frequencies were estimated by the gene-counting method, and the χ 2 test was used to identify a departure from Hardy-Weinberg equilibrium. Each polymorphism was assessed according to dominant, recessive, and additive genetic models. The odds ratio and 95% confidence interval of each genotype conferring to AMI risk were also calculated. Statistical significance was defined as the P value lower than 0.05, and all statistical methods were performed using the commercial statistical package software, SPSS 13.0, Windows version (SPSS, Chicago, IL).
Results
The allele frequency of the LTA 252A/G, 804C/A, and LGALS2 3279C/T gene polymorphisms among different subjects in this study are shown in Table 1 . Data from these 3 SNPs were available in 117 AMI cases and 165 normal controls. The mean age was 60 in cases and 52 in controls. Associations between AMI onset with homozygous 252G allele (χ 2 =14.9, P<0.0001; OR=1.786, 95% CI=1.37-2.32) and homozygous 804A allele (χ 2 =6.0, P=0.014; OR=1.414, 95% CI=1.07-1.85) carriage of LTA gene were obtained by comparing AMI patients with normal control subjects in a recessive association model but not in LGALS2 3279C/T polymorphism (χ 2 =0.3, P=0.562; OR=1.090, 95% CI=0.81-1.45). In addition, the normal subjects were subdivided into 2 subgroups (IIA and IIB), as previous studies suggested. 16 The association of LTA gene polymorphisms with the onset of AMI still exists (χ 2 =11.3, P=0.001, OR=1.587, 95% CI=1.25-2.00; χ 2 =7.3, P=0.007, OR=1.356, 95% CI=1.12-1.63); however, the A homozygosity of 804C/A polymorphism of the LTA gene might not directly modulate AMI risk. Although it may correlate with the prevalence of CAD, rather than the onset of AMI, since there was no significant difference in genetic frequency distribution between AMI patients and the control group IIA (non-AMI subjects). A statistically significant difference was found when compared to control group IIB (χ 2 =9.5, P=0.002, OR=1.384, 95% CI=1.13-1.68) ( Table 2) .
Furthermore, a susceptible haplotype of LTA was analyzed since 2 polymorphisms might have an additive effect in the influence on the mRNA transcription level and protein expression, finally conferring AMI risk. Consequently, predisposing haplotypes of the LTA gene was discovered as 252 G allele coupled with 804 C or A allele, which were associated with the onset of AMI after performing χ 2 and spearman correlation tests among different subjects (AMI vs all normal subjects, χ 2 =8.84, P=0.003;) ( Table 3 and Table 4 ). Genetic factors may contribute independently or could coordinate with other factors in the transfer of disease risk.
Discussion
Lymphotoxin-alpha is a member of the TNF family and plays a critical role in inflammation. It is located within the human leukocyte antigen class III gene cluster on human chromosome 6p21. 11 Many studies have focused on TNF-α as a key cytokine involved in heart failure and atherosclerosis. 17, 18 Lymphotoxin-alpha is a cytokine produced in early stages of vascular inflammatory processes. It is structurally similar to TNF-α and has an important role in the inflammatory response by inducing monocyte migration, as well as by promoting lymphocyte activation and proliferation. 19 Lymphotoxin-alpha and TNF-α share a common receptor controlling the expression of vascular endothelial cell adhesion molecules and nitric oxide production. Lymphotoxin-alpha is expressed in atherosclerotic plaques in animal models and has been implicated in the pathogenesis of atherosclerosis and coronary heart disease (CHD). 20 The animal model of gene knockout strategy has suggested that the LTA may be more important than TNF-α in proatherogenic response; LTA deficiency resulted in a 62% reduction in the size of atherosclerotic lesions. 20 Although this cytokine has been widely investigated to clarify its association with systemic inflammation in the past, the role of LTA in the pathology of CHD has not been fully elucidated; the only convergent point is vascular inflammations. To date, 7 common SNP sites with a functional significance of LTA have reported it is highly associated with the onset of cardiovascular disease. However, these findings pose controversial opinions. One of the most important polymorphisms is an A/G substitution at nucleotide position 252 (A252G) reported to be associated with increased transcriptional activities or elevated C-reactive protein. 21 Moreover, 804C/A polymorphism within exon3 links to the 252G allele, which increases mRNA expression of VCAM1, were also reported. 14 These SNPs seem to be involved in the inflammation both qualitatively and quantitatively, modifying the function of the LTA protein, and thereby conferring Ozaki and colleagues reported in a recessive model the SNPs 252A/G and 804C/A of the LTA gene were associated with odds ratios for MI of 1.71 (95% CI: 1.24-2.36) and 1.78 (95% CI: 1.39-2.27), respectively. 13 Concordance results obtained in our study were expected. The odd ratios for MI were 1.786 (95% CI: 1.37-2.32) and 1.414 (95% CI: 1.07-1.85). In the study, 2-stage designing was used, in which 65,671 genetic markers in 13,738 genes were initially screened for the 94 MI cases and 658 controls; 1% of markers appearing as most strongly associated with MI were re-examined further in 1,133 MI cases and 1,006 controls. Then, 252G/A, 804C/A of LTA, and 3279 C/T of LGALS2 were claimed to be highly associated with AMI in the Japanese population. 22 Lymphotoxin-alpha genetic variants not only correlated to the onset of AMI, but 252G allele-carrying individuals also possessed a higher ratio of recurrent cardiovascular events, even death, via long-term follow-up survey. 12 In spite of the several well-known environmental predictors of the prognosis of MI, such as high age, diabetes mellitus, hypertension, time to revascularization, severity of MI, and therapeutic interventions, 252G allele of LTA was identified as a predictor of death independent from these known predictors via Cox multivariate analysis. 12 In contrast, despite the positive impact, another largescale case-control study of 6,928 heart attack survivors and 2,712 unrelated controls in the United Kingdom reported no significant association of LTA with CHD risk after performing meta-analysis of the recent 8 independent related researches. 15 Clarke and colleagues advised that previous associations established by Japanese investigators may represent false-positive results since they were identified by a relatively small number of cases. 15 For this part, a major problem in genetic association studies has been the high proportion of false-positive results suggested by studies involving relatively small numbers of disease cases that have never been declared.
Alternatively, it may reflect an imbalance in the control population, which was selected from several different population sources, since significant departures from the Hardy-Weinberg equilibrium were observed in genotype distributions in case and control samples in the Ozaki study. This may be due to population stratification. 22 In addition, another 2 case-control studies carried out in Japanese populations have reported conflicting results, with 1 appearing to confirm the association of 252A/G to the risk of MI. 12, 16 Thus, the exact association between these 2 polymorphisms of LTA with an onset or prognosis of AMI must be elucidated using representative larger samples and by comparing results across different ethnic populations in future studies. In the meantime, further work is necessary to uncover pathways or mechanisms involved in the proatherogenic-inducing process.
The LGALS2 gene is a member of the galactose-binding lectin family, whose function has not been well characterized. The LGALS2 gene was originally reported as a proteinbinding partner of LTA, and its expression was suspected to modulate the LTA expression result of inflammation of an infracted heart. 10 The homozygous C allele of 3279C/T polymorphism was identified as a predisposing factor to the onset of MI. 10 The C variant of this polymorphism might influence the expression of mRNA transcripts and its protein production. Excess galectin-2 protein might bind with LTA and transport to extracellular locations via the microtubule system in vitro. 10 Conversely, C→T substitution repressed the transcriptional level of galectin-2 in twofold and altered the secretion of LTA. This genetic variation repressing galectin-2 levels leads to the inhibition of LTA secretion into the culturing medium. 10 This substitution might result in reduced proinflammatory events of atherosclerotic lesions due to marginally down-regulating LTA secretions. Moreover, polymorphism was also suspected to be involved in glucose-insulin regulation due to a cross-sectional genetic study among the British. This study showed that fasting plasma glucose and serum insulin were statistically and significantly associated with LGALS2 3279C/T polymorphism, with the association being independent of BMI and WHR. 23 However, a controversial report was published and indicated no association between polymorphism and MI among British Caucasians. 24 We also could not identify an association with the onset of AMI within the Taiwanese sample. Contentious findings, which have commonly occurred in recent SNPs studies, are probably due to ethnic differences or sampling problems. Apart from these reasons, galectin-2 might still be 1 of the binding partners of LTA. More likely, it is not the major class, and another molecule trigger with more effective LTA secretion in vivo should be determined. Thus, more population-based and gene-association studies are warranted to identify these points of view. LM 
